Expiry of Share Options

RNS Number : 0694F

MGC Pharmaceuticals Limited

13 July 2021

 

Expiry of Share Options and Appendix 3H

13 July 2021

ASX, LSE Code: MXC

MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the Company') wishes to advise that 10,000,000 Share Options on issue expired on 30 June 2021.

Further information can be found here

-Ends-

Authorised for release by David Lim, Company Secretary, for further information, please contact:

MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director [phone] [e-mail]	PR/IR Advisors - Media & Capital Partners Rod Hinchcliffe (IR) [phone] [e-mail]
UK Broker - Turner Pope Andy Thacker [e-mail] Zoe Alexander [phone] [e-mail]	UK PR Advisors - Tavistock Charles Vivian [phone] [e-mail] Tim Pearson [phone] [e-mail]

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally.  The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels :

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

END

 

 

MSCFIFEADLIVLIL